RecruitingNot Applicable

Non-invasive Evaluation of the Predictive Value of CEUS and SWE in ACLF, Renal Failure and Hepatorenal Syndrome

Germany1,000 participantsStarted 2021-01-01

Plain-language summary

Evaluation of non-invasive prognostic parameters in patients developing ACLF and renal failure in patients receiving and not receiving transjugular intrahepatic portosystemic shunt (TIPS). Patients are cared according to the local standardized follow up program. Clinical and laboratory data from standard patient care are evaluated for potential prognostic value.

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All patients with portal hypertension and kidney failure Exclusion Criteria: * no consent, no kidney failure, no portal hypertension

What they're measuring

Survival

Timeframe: up to 10 years

Trial details

NCT IDNCT04446858

SponsorUniversity Hospital, Bonn

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2030-07-01

Contact for this trial

Michael Praktiknjo, MD

+49(0)228-287 15770 michael.praktiknjo@ukbonn.de

View on ClinicalTrials.gov More Kidney Failure, Acute trials